• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤学家主导的卵巢癌临床 BRCA 基因检测:一项 255 例患者的研究及其对管理的影响。

Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.

机构信息

National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, UK.

Department of Medical Oncology, Hammersmith Hospital, London, UK.

出版信息

Sci Rep. 2020 Feb 25;10(1):3390. doi: 10.1038/s41598-020-60149-5.

DOI:10.1038/s41598-020-60149-5
PMID:32098980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7042365/
Abstract

Although guidelines recommend BRCA testing for all women with non-mucinous epithelial ovarian cancer, there is significant variability in access to testing across the UK. A germline BRCA mutation (BRCAm) in ovarian cancer patients provides prognostic and predictive information and influences clinical management, such as the use of PARP inhibitors, which have demonstrated a progression-free survival benefit in the BRCAm cohort. Additionally, the finding of a BRCAm has significant implications for patients and their families in terms of cancer risk and prevention. We studied the impact of a newly-formed, oncologist-led 'mainstreaming' germline BRCA testing pathway in 255 ovarian cancer patients at Imperial College NHS Trust. Prior to the establishment of 'mainstreaming', uptake of germline BRCA testing was 14% with a mean turnaround time of 148.2 calendar days. The 'mainstreaming' approach led to a 95% uptake of germline BRCA testing and a mean turnaround time of 20.6 days. Thirty-four (13.33%) BRCAm patients were identified. At the time of data collection nine BRCAm patients had received a PARP inhibitor off-trial, three had entered a PARP inhibitor trial and 5 were receiving platinum-based chemotherapy with a plan to receive PARP inhibitor maintenance. This study provides further evidence of the impact of oncologist-led 'mainstreaming' programs.

摘要

虽然指南建议对所有非黏液上皮性卵巢癌女性进行 BRCA 检测,但英国各地的检测可及性存在显著差异。卵巢癌患者中的种系 BRCA 突变(BRCAm)提供了预后和预测信息,并影响了临床管理,例如 PARP 抑制剂的使用,其在 BRCAm 队列中显示出无进展生存期获益。此外,BRCAm 的发现对患者及其家属在癌症风险和预防方面具有重要意义。我们研究了在帝国理工学院 NHS 信托基金的 255 名卵巢癌患者中,新成立的、由肿瘤学家主导的“主流”种系 BRCA 检测途径的影响。在建立“主流”之前,种系 BRCA 检测的吸收率为 14%,平均周转时间为 148.2 个日历日。“主流”方法导致种系 BRCA 检测吸收率达到 95%,平均周转时间为 20.6 天。确定了 34 名(13.33%)BRCAm 患者。在数据收集时,9 名 BRCAm 患者接受了 PARP 抑制剂的试验外治疗,3 名患者进入了 PARP 抑制剂试验,5 名患者正在接受铂类化疗,并计划接受 PARP 抑制剂维持治疗。这项研究进一步证明了肿瘤学家主导的“主流”计划的影响。

相似文献

1
Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.肿瘤学家主导的卵巢癌临床 BRCA 基因检测:一项 255 例患者的研究及其对管理的影响。
Sci Rep. 2020 Feb 25;10(1):3390. doi: 10.1038/s41598-020-60149-5.
2
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.奥拉帕利单药维持治疗铂敏感复发性浆液性卵巢癌患者的总生存期:一项随机、安慰剂对照、双盲、2 期临床试验的更新分析。
Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.
3
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.奥拉帕利维持治疗铂类敏感复发性上皮性卵巢癌伴 BRCA 突变患者:基于后进展多聚(腺苷二磷酸核糖)聚合酶抑制剂治疗的总生存调整。
Cancer. 2016 Jun 15;122(12):1844-52. doi: 10.1002/cncr.29995. Epub 2016 Apr 8.
4
Epithelial ovarian cancer and brain metastases: might the status, PARP inhibitor administration, and surgical treatment impact the survival?上皮性卵巢癌脑转移:状态、PARP 抑制剂治疗和手术治疗是否会影响生存?
Int J Gynecol Cancer. 2024 Jan 5;34(1):88-98. doi: 10.1136/ijgc-2023-004980.
5
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.胚系BRCA1/2突变的晚期卵巢癌患者对PARP抑制剂奥拉帕尼抗肿瘤反应的基线临床预测指标。
Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.
6
Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.简化的肿瘤专家主导的 BRCA 基因突变检测和咨询模型在卵巢癌患者中的评估。
J Clin Oncol. 2018 May 1;36(13):1300-1307. doi: 10.1200/JCO.2017.76.2781. Epub 2018 Mar 20.
7
PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.聚腺苷二磷酸核糖聚合酶抑制剂降低了携带 BRCA 基因突变的卵巢癌患者对后续铂类化疗的反应。
Anticancer Drugs. 2021 Nov 1;32(10):1086-1092. doi: 10.1097/CAD.0000000000001219.
8
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline mutations: OPINION Phase IIIb study design.奥拉帕利单药维持治疗无胚系突变的铂敏感复发性卵巢癌:IIIb 期研究设计。
Future Oncol. 2019 Nov;15(32):3651-3663. doi: 10.2217/fon-2019-0343. Epub 2019 Sep 25.
9
Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.复发性卵巢癌的一线 PARP 抑制剂维持治疗:妇科肿瘤学会实践声明。
Gynecol Oncol. 2020 Oct;159(1):8-12. doi: 10.1016/j.ygyno.2020.07.097. Epub 2020 Aug 7.
10
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?PARP抑制剂在卵巢癌治疗中的地位如何?
Curr Oncol Rep. 2016 May;18(5):29. doi: 10.1007/s11912-016-0515-z.

引用本文的文献

1
Optimizing risk-reducing surgery and aspirin decision aids for Lynch syndrome carriers using the person-based approach: A think-aloud interview study.采用基于个体的方法优化林奇综合征携带者的降低风险手术和阿司匹林决策辅助工具:一项出声思考访谈研究。
J Genet Couns. 2025 Aug;34(4):e70089. doi: 10.1002/jgc4.70089.
2
BRCA genetic testing and counseling in breast cancer: how do we meet our patients' needs?乳腺癌中的BRCA基因检测与咨询:我们如何满足患者的需求?
NPJ Breast Cancer. 2024 Sep 5;10(1):77. doi: 10.1038/s41523-024-00686-8.
3
Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer.对新诊断的浸润性乳腺癌进行通用基因检测。
JAMA Netw Open. 2024 Sep 3;7(9):e2431427. doi: 10.1001/jamanetworkopen.2024.31427.
4
Racial Disparities in Breast Cancer Genetic Testing May be Mitigated by Counseling.种族差异可能通过咨询来减轻乳腺癌基因检测的影响。
Ann Surg Oncol. 2024 Aug;31(8):5197-5204. doi: 10.1245/s10434-024-15434-2. Epub 2024 May 29.
5
Hereditary genetic testing and mainstreaming: a guide for surgeons.遗传性基因检测与主流化:外科医生指南
Ann R Coll Surg Engl. 2024 Apr;106(4):300-304. doi: 10.1308/rcsann.2024.0029.
6
Development of an Electronic Decision Aid Tool to Facilitate Mainstream Genetic Testing in Ovarian Cancer Patients.开发一种电子决策辅助工具以促进卵巢癌患者的主流基因检测
Oncologist. 2024 May 3;29(5):e665-e671. doi: 10.1093/oncolo/oyad328.
7
Co-design of patient information leaflets for germline predisposition to cancer: recommendations for clinical practice from the UK Cancer Genetics Group (UKCGG), Cancer Research UK (CRUK) funded CanGene-CanVar Programme and the Association of Genetic Nurse Counsellors (AGNC).癌症种系易感性患者信息单页的共同设计:英国癌症遗传学组(UKCGG)、英国癌症研究中心(CRUK)资助的 CanGene-CanVar 项目和遗传护士顾问协会(AGNC)为临床实践提供的建议。
J Med Genet. 2024 Jan 19;61(2):142-149. doi: 10.1136/jmg-2023-109440.
8
Patient decisions regarding cancer gene panel testing: An exploratory study.患者对癌症基因检测的决策:一项探索性研究。
J Genet Couns. 2024 Oct;33(5):1103-1112. doi: 10.1002/jgc4.1824. Epub 2023 Nov 11.
9
2023 Canadian Urological Association guideline: Genetic testing in prostate cancer.2023年加拿大泌尿外科协会指南:前列腺癌的基因检测
Can Urol Assoc J. 2023 Oct;17(10):314-325. doi: 10.5489/cuaj.8588.
10
Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake.胰腺癌中的胚系BRCA检测:提高认知度、检测时机、周转效率及接受度。
Ther Adv Med Oncol. 2023 Sep 15;15:17588359231189127. doi: 10.1177/17588359231189127. eCollection 2023.